NCT05714683View on ClinicalTrials.gov

Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

Not yet recruitingOBSERVATIONAL

Enrollment

600

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

October 30, 2026

Study Completion Date

October 30, 2026

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Semaglutide

All participants will be treated with oral semaglutide for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS. The prescription of semaglutide will be separated from the decision to include the participant in the study.